CYDY - CytoDyn provides updates on leronlimab HIV extension arm; to hold webcast on May 5 on multiple initiatives

CytoDyn (CYDY) announces a comprehensive update on three continuing extension studies with leronlimab as a treatment for HIV. Clinical results from multiple trials show that Vyrologix can significantly reduce the viral burden in people infected with HIV.Moreover, a Phase 2 trial demonstrated that Vyrologix monotherapy could prevent viral escape in HIV-infected patients.There have been 66 patients from the original trials still receiving Vyrologix in an open label design with an exposure range of 4-7 years.  No significant adverse safety issues reported."While we are learning more about the unique binding of Vyrologix to CCR5 and how this impacts efficacy in other indications, including COVID and oncology, safety data from our cumulative trials remains excellent for almost 7 years and close to 1,200 patients,” commented Chris Recknor, M.D., Chief Operating Officer. CytoDyn has successfully completed a Phase 3 trial using leronlimab combined with standard antiretroviral therapies in HIV-infected treatment-experienced patients. The company expects

For further details see:

CytoDyn provides updates on leronlimab HIV extension arm; to hold webcast on May 5 on multiple initiatives